Kanazawa University, have captured real-time images showing how a key brain enzyme organizes itself to help memory formation.
Parkinson's disease (PD) is a debilitating and progressive neurodegenerative disorder caused by the loss of ...
Schrödinger, Inc. (Nasdaq: SDGR) provided an update on its progress across the business in 2025 and announced its strategic priorities for 2026. The company is continuing to focus on advancing its ...
Lynk’s zemprocitinib commercial partner, Simcere, will now continue the JAK inhibitor’s development across China in RA.
The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...
Nurix Therapeutics (NRIX) stock: bexobrutideg’s BTK degradation shows strong efficacy in B-cell cancers, backed by $650M cash ...
Modern medical breakthroughs save lives in ways that feel miraculous, showing how faith and science can work together as ...
Under the agreement, KeifeRx will conduct a research program intended to generate key pre-IND outputs to support Amneal’s evaluation of KFRX06 and inform potential next-stage development. Financial ...
Takeda Pharmaceuticals Co. Ltd.’s oral tyrosine kinase 2 inhibitor, zasocitinib (TAK-279), met the co-primary endpoints and ...
Hutchmed Ltd. plans to file a second NDA in China for sovleplenib, a novel spleen tyrosine kinase inhibitor, based on positive phase II/III findings in warm antibody autoimmune hemolytic anemia.
HER2CLIMB-05 trial evaluated Tukysa in combination with Herceptin and Perjeta for HER2-positive metastatic breast cancer, ...
Enliven Therapeutics (EVN) stock jumps as the company post initial early-stage trial data for its lead asset ELVN-001 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback